Ambeed.cn

首页 / Levosimendan/左西孟旦

Levosimendan/左西孟旦 {[allProObj[0].p_purity_real_show]}

货号:A103792 同义名: Simsndan; OR-1259

Levosimendan is a calcium sensitiser used in the management of acutely decompensated congestive heart failure.

Levosimendan/左西孟旦 化学结构 CAS号:141505-33-1
Levosimendan/左西孟旦 化学结构
CAS号:141505-33-1
Levosimendan/左西孟旦 3D分子结构
CAS号:141505-33-1
Levosimendan/左西孟旦 化学结构 CAS号:141505-33-1
Levosimendan/左西孟旦 3D分子结构 CAS号:141505-33-1
规格 价格 会员价 库存 数量
{[ item.pr_size ]}

{[ getRatePrice(item.pr_rmb, 1,1) ]}

{[ getRatePrice(item.pr_rmb_sale, 1,1) ]} {[ suihuo_tips(item.pr_tag_price) ]}

{[ getRatePrice(item.pr_rmb, 1,1) ]}

{[ getRatePrice(item.pr_rmb,item.pr_rate,1) ]} {[ suihuo_tips(item.pr_tag_price) ]}
{[ getRatePrice(item.pr_rmb, 1,1) ]}{[ suihuo_tips(item.pr_tag_price) ]} {[ getRatePrice(item.pr_rmb_sale, 1,1) ]} {[ getRatePrice(item.pr_rmb,item.pr_rate,item.mem_rate) ]} {[ getRatePrice(item.pr_rmb,1,item.mem_rate) ]} 现货 1周 咨询 - +
购物车0 收藏 询单

Levosimendan/左西孟旦 纯度/质量文件 产品仅供科研

货号:A103792 标准纯度: {[allProObj[0].p_purity_real_show]}
批次查询: 批次纯度:

全球学术期刊中引用的产品

Science, 2025, 387(6729): eadp5637. Ambeed. [ A875019 ]
Nat. Electron., 2025, 8, 66-74. Ambeed. [ A100095 ]
Adv. Mater., 2025, 2416621. Ambeed. [ A255324 , A420052 ]
Adv. Mater., 2025, 2410493. Ambeed. [ A838608 ]
Adv. Mater., 2025, 2420319. Ambeed. [ A106129 ]
更多 >

Levosimendan/左西孟旦 生物活性

描述 Levosimendan is a calcium sensitiser and potassium channel-opener used in the management of acutely decompensated congestive heart failure. The principal pharmacological effects of levosimendan are (a) increased cardiac contractility by calcium sensitisation of troponin C, (b) vasodilation, and (c) cardioprotection. Levosimendan also has favourable effects on neurohormone levels in heart failure patients. Levosimendan is generally well tolerated in acute heart failure patients: the most common adverse events encountered in this setting are hypotension, headache, atrial fibrillation, hypokalaemia and tachycardia[3]. Levosimendan increases contractile force of the heart and improves vasodilation. It increases the heart's sensitivity to calcium, thereby increasing cardiac contractility. Its mechanism of action is via the increased calcium sensitivity of myocytes by binding to cardiac troponin C in a calcium-dependent manner. Its opening of adenosine triphosphate-sensitive potassium channels in vascular smooth muscle leads to a vasodilatory effect and smooth muscle relaxatio[4]. Levosimendan possesses an isoform-selective phosphodiesterase-inhibitory effect[5]. Levosimendan might reduce mortality in cardiac surgery and cardiology settings of adult patients[6].

Levosimendan/左西孟旦 临床研究

NCT号 适应症或疾病 临床期 招募状态 预计完成时间 地点
NCT03281317 - Recruiting December 15, 2020 France ... 展开 >> CHU Amiens Picardie Recruiting Amiens, France, 80054 Contact: Pierre-Gregoire GUINOT 收起 <<
NCT03632837 Cardiac Arrest ... 展开 >> Resuscitation Inflammation Multi-Organ Disorder 收起 << Not Applicable Recruiting September 2019 Germany ... 展开 >> University Hospital Hamburg-Eppendorf Recruiting Hamburg, Germany, 20246 Contact: Jens Kubitz, Prof. Dr.    +49 (0) 40 7410 - 52415    j.kubitz@uke.de    Contact: Eike Pfefferkorn, Dr.       e.pfefferkorn@uke.de 收起 <<
NCT02627378 MERS-CoV Infection ... 展开 >> Refractory Hypoxemia 收起 << Phase 1 Completed - Saudi Arabia ... 展开 >> Dammam University KFHU Al-Khobar, EP, Saudi Arabia, 31952 收起 <<

Levosimendan/左西孟旦 参考文献

[1]Yokoshiki H, Katsube Y, et al. Levosimendan, a novel Ca2+ sensitizer, activates the glibenclamide-sensitive K+ channel in rat arterial myocytes. Eur J Pharmacol. 1997 Aug 27;333(2-3):249-59.

[2]Haikala H, Kaivola J, et al. Cardiac troponin C as a target protein for a novel calcium sensitizing drug, levosimendan. J Mol Cell Cardiol. 1995 Sep;27(9):1859-66.

[3]Nieminen MS, Fruhwald S, Heunks LM, Suominen PK, Gordon AC, Kivikko M, Pollesello P. Levosimendan: current data, clinical use and future development. Heart Lung Vessel. 2013;5(4):227-45

[4]Levin A, Paret G. Levosimendan. J Pediatr Intensive Care. 2013 Sep;2(3):95-103

[5]Papp Z, Édes I, Fruhwald S, De Hert SG, Salmenperä M, Leppikangas H, Mebazaa A, Landoni G, Grossini E, Caimmi P, Morelli A, Guarracino F, Schwinger RH, Meyer S, Algotsson L, Wikström BG, Jörgensen K, Filippatos G, Parissis JT, González MJ, Parkhomenko A, Yilmaz MB, Kivikko M, Pollesello P, Follath F. Levosimendan: molecular mechanisms and clinical implications: consensus of experts on the mechanisms of action of levosimendan. Int J Cardiol. 2012 Aug 23;159(2):82-7

[6]Landoni G, Biondi-Zoccai G, Greco M, Greco T, Bignami E, Morelli A, Guarracino F, Zangrillo A. Effects of levosimendan on mortality and hospitalization. A meta-analysis of randomized controlled studies. Crit Care Med. 2012 Feb;40(2):634-46

Levosimendan/左西孟旦 实验方案

计算器
存储液制备 1mg 5mg 10mg

1 mM

5 mM

10 mM

3.57mL

0.71mL

0.36mL

17.84mL

3.57mL

1.78mL

35.68mL

7.14mL

3.57mL

Levosimendan/左西孟旦 技术信息

CAS号141505-33-1
分子式C14H12N6O
分子量 280.29
SMILES Code N#CC(C#N)=NNC1=CC=C(C([C@H](C)C2)=NNC2=O)C=C1
MDL No. MFCD00867135
别名 Simsndan; OR-1259; simendan; Simadax; OR-1855; dextrosimendan; (-)-OR-1259; Levosimedan; Levosimendanum; Simdax; (R)-Simendan
运输蓝冰
InChI Key WHXMKTBCFHIYNQ-SECBINFHSA-N
Pubchem ID 3033825
存储条件

In solvent -20°C:3-6个月-80°C:12个月

Pure form Sealed in dry, room temperature

溶解方案

DMSO: 50 mg/mL(178.39 mM),注意:DMSO长时间开封后,会吸水并导致溶解能力下降,请避免使用长期开封的DMSO

动物实验配方

5% DMSO+40%PEG 300+5%Tween80+50%water 5 mg/mL

Ambeed 相关网站 Ambeed.cn Ambeed.com
Ambeed
关于我们
联系我们
资讯中心
网站地图
产品手册
  • 批次文件查询
  • 客户支持
    技术支持
    专业术语
    缩略词释义
    质量手册
    产品咨询
    计算器
    活动政策
    订购方法
    积分商城
    活动声明
    联系我们
    400-920-2911 sales@ambeed.cn tech@ambeed.cn
    Ambeed 只为有资质的科研机构、医药企业基于科学研究或药证申报的用途提供医药研发服务,不为任何个人或者非科研性质用途提供服务。